STL Volume 31 Number 1

Deuruxolitinib (FDA-approved July 2024) is an oral JAK1/JAK2 inhibitor for severe alopecia areata. Learn about its mechanism, THRIVE-AA trial results showing rapid hair regrowth, safety profile, and how it compares to baricitinib and ritlecitinib.

Discover icotrokinra, a groundbreaking oral peptide that targets the IL-23 receptor to treat moderate-to-severe plaque psoriasis. Clinical trials show it delivers biologic-like skin clearance in a convenient once-daily pill.

Update on Calcipotriene and betamethasone dipropionate cream, 0.005%/0.064% (Wynzora®), Roflumilast foam 0.3% (Zoryve®), Roflumilast cream 0.05% (Zoryve®), and Lidocaine topical system 10% (Bondlido®)